[
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "Which genetic disorder caused by mutations on chromosome 2 leads to the greatest increases to patients' basal metabolic rate? \n\nAnswer Choices:\nA. Alstr\u00f6m syndrome\nB. Menkes disease\nC. Gilbert's syndrome\nD. Ehlers\u2013Danlos syndrome\nE. Harlequin-type ichthyosis\nF. Graves' disease\nG. Sepsis\nH. Cystic fibrosis\nI. Familial neuroblastoma\n\nJ. Multiple Endocrine Neoplasia Type 2 (MEN2)"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G",
                  "H",
                  "I",
                  "J"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762211263-qChmv4fSJ099fuOr7hVh",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"I. Familial neuroblastoma \u2014 germline activating mutations in the ALK gene on chromosome 2 (2p23) cause familial neuroblastoma; catecholamine-secreting tumors produce high levels of epinephrine/norepinephrine and produce a hypermetabolic state, raising basal metabolic rate. (Other listed disorders on chr2 \u2014 e.g. Alstr\u00f6m, Gilbert, ABCA12 ichthyosis \u2014 do not produce such marked BMR increases.)\",\"answer_letter\":\"I\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Clarifying genetic disorders**\n\nOkay, so Menkes disease is caused by the ATP7A gene on the X chromosome, not chromosome 2. Gilbert's syndrome is linked to the UGT1A1 gene on chromosome 2q37, leading to mild unconjugated hyperbilirubinemia without affecting the basal metabolic rate. As for Ehlers-Danlos syndrome (EDS), it has different types with genes on various chromosomes, including COL5A1 on chromosome 9 and COL3A1 on chromosome 2q. Harlequin-type ichthyosis is caused by the ABCA12 gene on chromosome 2q35, resulting in severe skin thickening but also not increasing BMR. Graves' disease is an autoimmune issue, not linked to chromosome 2.**Identifying genetic disorders on chromosome 2**\n\nGraves' disease causes hyperthyroidism and significantly raises the basal metabolic rate \u2014 but it\u2019s not related to chromosome 2 mutations. \n\nLooking at genetic disorders associated with chromosomal mutations, we have Alstr\u00f6m syndrome (ALMS1 on chr2), Gilbert's syndrome (UGT1A1 on chr2), and specific Ehlers-Danlos types like vascular (COL3A1 on chr2). Harlequin ichthyosis has the ABCA12 gene also on chr2. \n\nCystic fibrosis doesn\u2019t involve chromosome 2, while familial neuroblastoma relates to MYCN and ALK genes on chromosome 2. I\u2019m considering if neuroblastoma affects metabolic rates via catecholamines, but I'm uncertain about that connection.**Exploring genetic disorders and BMR**\n\nMultiple Endocrine Neoplasia Type 2 is caused by a RET mutation on chromosome 10, so it\u2019s not relevant here. Sepsis isn\u2019t a genetic disorder. Graves' disease does increase basal metabolic rate but involves TSH receptor mutations on chromosome 14, not chromosome 2. \n\nNow, looking at potential answers, Alstr\u00f6m syndrome results in obesity and insulin resistance, which might correlate with a decreased BMR. Familial neuroblastoma, caused by ALK mutations on chromosome 2, could lead to catecholamine release, possibly raising BMR, but I\u2019m unsure if it surpasses Graves' disease. However, since Graves' isn\u2019t from chromosome 2, that complicates things.**Analyzing disorders for BMR impact**\n\nThe question looks for a genetic disorder linked to chromosome 2 that increases basal metabolic rate. I need to identify those disorders and evaluate their effects on BMR. \n\nAlstr\u00f6m syndrome leads to obesity and insulin resistance, likely correlating with a decreased BMR. Gilbert's syndrome mostly causes mild jaundice with no clear impact on metabolic rate. Ehlers-Danlos (vascular type) doesn't increase BMR either. Harlequin ichthyosis might result in some hypermetabolism due to severe skin issues, but that's uncertain. Familial neuroblastoma could raise catecholamines, which might elevate metabolic rates, so it seems more promising in terms of increasing BMR compared to others.**Determining BMR increases from genetic disorders**\n\nFamilial neuroblastoma is indeed caused by the ALK gene on chromosome 2, which makes it a candidate for the answer. However, I'm considering if it has a greater effect on BMR compared to other conditions. \n\nAmong the options on chromosome 2, Alstr\u00f6m syndrome, Gilbert's syndrome, Ehlers-Danlos syndrome, and Harlequin ichthyosis are all relevant. Alstr\u00f6m syndrome typically leads to decreased BMR due to obesity. Harlequin ichthyosis might increase BMR due to high energy demands, but familial neuroblastoma seems to cause catecholamine overproduction, potentially raising BMR more significantly. So, I'll conclude that the answer is I: familial neuroblastoma due to its catecholamine effects.",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Clarifying genetic disorders**\n\nOkay, so Menkes disease is caused by the ATP7A gene on the X chromosome, not chromosome 2. Gilbert's syndrome is linked to the UGT1A1 gene on chromosome 2q37, leading to mild unconjugated hyperbilirubinemia without affecting the basal metabolic rate. As for Ehlers-Danlos syndrome (EDS), it has different types with genes on various chromosomes, including COL5A1 on chromosome 9 and COL3A1 on chromosome 2q. Harlequin-type ichthyosis is caused by the ABCA12 gene on chromosome 2q35, resulting in severe skin thickening but also not increasing BMR. Graves' disease is an autoimmune issue, not linked to chromosome 2.**Identifying genetic disorders on chromosome 2**\n\nGraves' disease causes hyperthyroidism and significantly raises the basal metabolic rate \u2014 but it\u2019s not related to chromosome 2 mutations. \n\nLooking at genetic disorders associated with chromosomal mutations, we have Alstr\u00f6m syndrome (ALMS1 on chr2), Gilbert's syndrome (UGT1A1 on chr2), and specific Ehlers-Danlos types like vascular (COL3A1 on chr2). Harlequin ichthyosis has the ABCA12 gene also on chr2. \n\nCystic fibrosis doesn\u2019t involve chromosome 2, while familial neuroblastoma relates to MYCN and ALK genes on chromosome 2. I\u2019m considering if neuroblastoma affects metabolic rates via catecholamines, but I'm uncertain about that connection.**Exploring genetic disorders and BMR**\n\nMultiple Endocrine Neoplasia Type 2 is caused by a RET mutation on chromosome 10, so it\u2019s not relevant here. Sepsis isn\u2019t a genetic disorder. Graves' disease does increase basal metabolic rate but involves TSH receptor mutations on chromosome 14, not chromosome 2. \n\nNow, looking at potential answers, Alstr\u00f6m syndrome results in obesity and insulin resistance, which might correlate with a decreased BMR. Familial neuroblastoma, caused by ALK mutations on chromosome 2, could lead to catecholamine release, possibly raising BMR, but I\u2019m unsure if it surpasses Graves' disease. However, since Graves' isn\u2019t from chromosome 2, that complicates things.**Analyzing disorders for BMR impact**\n\nThe question looks for a genetic disorder linked to chromosome 2 that increases basal metabolic rate. I need to identify those disorders and evaluate their effects on BMR. \n\nAlstr\u00f6m syndrome leads to obesity and insulin resistance, likely correlating with a decreased BMR. Gilbert's syndrome mostly causes mild jaundice with no clear impact on metabolic rate. Ehlers-Danlos (vascular type) doesn't increase BMR either. Harlequin ichthyosis might result in some hypermetabolism due to severe skin issues, but that's uncertain. Familial neuroblastoma could raise catecholamines, which might elevate metabolic rates, so it seems more promising in terms of increasing BMR compared to others.**Determining BMR increases from genetic disorders**\n\nFamilial neuroblastoma is indeed caused by the ALK gene on chromosome 2, which makes it a candidate for the answer. However, I'm considering if it has a greater effect on BMR compared to other conditions. \n\nAmong the options on chromosome 2, Alstr\u00f6m syndrome, Gilbert's syndrome, Ehlers-Danlos syndrome, and Harlequin ichthyosis are all relevant. Alstr\u00f6m syndrome typically leads to decreased BMR due to obesity. Harlequin ichthyosis might increase BMR due to high energy demands, but familial neuroblastoma seems to cause catecholamine overproduction, potentially raising BMR more significantly. So, I'll conclude that the answer is I: familial neuroblastoma due to its catecholamine effects.",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "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",
                "id": "rs_050378ef3d4254f001690935c0370481959ce45f7e21399029",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762211263,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 1905,
        "prompt_tokens": 164,
        "total_tokens": 2069,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 1792,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.003851,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 4.1e-05,
          "upstream_inference_completions_cost": 0.00381
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "Which genetic disorder caused by mutations on chromosome 2 leads to the greatest increases to patients' basal metabolic rate? \n\nAnswer Choices:\nA. Alstr\u00f6m syndrome\nB. Menkes disease\nC. Gilbert's syndrome\nD. Ehlers\u2013Danlos syndrome\nE. Harlequin-type ichthyosis\nF. Graves' disease\nG. Sepsis\nH. Cystic fibrosis\nI. Familial neuroblastoma\n\nJ. Multiple Endocrine Neoplasia Type 2 (MEN2)"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G",
                  "H",
                  "I",
                  "J"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762211263-EE7UMfYaqbZDU8CGkLlQ",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"Familial neuroblastoma \u2014 germline activating mutations in ALK on chromosome 2 (2p23) predispose to neuroblastoma. Neuroblastomas are highly metabolic, often catecholamine\u2011secreting tumors that markedly raise patients\u2019 basal metabolic rate compared with the other listed disorders.\",\"answer_letter\":\"I\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Considering genetic disorders**\n\nI'm examining the question about which genetic disorder from chromosome 2 increases basal metabolic rate (BMR) the most. Graves' disease is a strong candidate for increasing BMR, but it\u2019s an autoimmune disorder and not necessarily linked to chromosome 2. I wonder if it\u2019s associated with any HLA markers. Among the potential options, I\u2019m thinking familial neuroblastoma due to ALK on chromosome 2 could be relevant since it raises catecholamines, which might actually raise metabolic rate. But would it surpass the increase seen in Graves' disease? Also, I need to confirm ALMS1 is on chromosome 2 and consider its effects.**Evaluating genetic disorders on chromosome 2**\n\nI\u2019m exploring genetic disorders linked to chromosome 2 that might increase basal metabolic rate (BMR). UGT1A1 for Gilbert's syndrome doesn\u2019t impact BMR, and while some Ehlers-Danlos genes are there, they likely don\u2019t either. Familial neuroblastoma associated with ALK on chromosome 2 seems promising because tumors can cause hypermetabolism and increase BMR due to cancer cachexia. I also considered MEN2, but since it\u2019s linked to RET on chromosome 10, it's not relevant here. I\u2019ll focus on familial neuroblastoma for its effects on BMR.**Analyzing answer choices for genetic disorders**\n\nI\u2019m looking at the answer choices related to chromosome 2 to see which one increases basal metabolic rate (BMR) the most. A few candidates include Alstr\u00f6m syndrome, Gilbert's syndrome, Harlequin ichthyosis, familial neuroblastoma, and potentially some collagen genes. None seem to cause hyperthyroidism, which can significantly elevate BMR. Familial neuroblastoma might increase catecholamines, potentially leading to hypermetabolism. However, Graves' disease, while not on chromosome 2, appears to increase BMR the most among all options presented.**Clarifying the prompt's requirements**\n\nThe prompt asks for a genetic disorder caused by mutations on chromosome 2 that also leads to the greatest increase in basal metabolic rate (BMR). It seems like I need to identify one disorder that meets both criteria. Familial neuroblastoma on chromosome 2 could be a candidate due to its potential to increase BMR through catecholamine secretion. However, I\u2019m still considering hyperthyroidism, especially Graves\u2019 disease, which significantly elevates BMR, but I doubt it\u2019s linked to chromosome 2. I\u2019ll need to stick with options that fit both constraints.**Evaluating familial neuroblastoma**\n\nI\u2019m checking the details around familial neuroblastoma, where ALK activation leads to catecholamine secretion. This can cause sympathetic hyperactivity and potentially moderate increases in basal metabolic rate (BMR). Harlequin ichthyosis could also cause increased energy loss, impacting BMR, but I suspect familial neuroblastoma has a larger effect due to tumor metabolic demand. The ALK gene is indeed on chromosome 2. I\u2019m leaning toward option I, as the catecholamine secretion from neuroblastoma contributes significantly to higher BMR. I'll provide a concise justification for this selection.",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Considering genetic disorders**\n\nI'm examining the question about which genetic disorder from chromosome 2 increases basal metabolic rate (BMR) the most. Graves' disease is a strong candidate for increasing BMR, but it\u2019s an autoimmune disorder and not necessarily linked to chromosome 2. I wonder if it\u2019s associated with any HLA markers. Among the potential options, I\u2019m thinking familial neuroblastoma due to ALK on chromosome 2 could be relevant since it raises catecholamines, which might actually raise metabolic rate. But would it surpass the increase seen in Graves' disease? Also, I need to confirm ALMS1 is on chromosome 2 and consider its effects.**Evaluating genetic disorders on chromosome 2**\n\nI\u2019m exploring genetic disorders linked to chromosome 2 that might increase basal metabolic rate (BMR). UGT1A1 for Gilbert's syndrome doesn\u2019t impact BMR, and while some Ehlers-Danlos genes are there, they likely don\u2019t either. Familial neuroblastoma associated with ALK on chromosome 2 seems promising because tumors can cause hypermetabolism and increase BMR due to cancer cachexia. I also considered MEN2, but since it\u2019s linked to RET on chromosome 10, it's not relevant here. I\u2019ll focus on familial neuroblastoma for its effects on BMR.**Analyzing answer choices for genetic disorders**\n\nI\u2019m looking at the answer choices related to chromosome 2 to see which one increases basal metabolic rate (BMR) the most. A few candidates include Alstr\u00f6m syndrome, Gilbert's syndrome, Harlequin ichthyosis, familial neuroblastoma, and potentially some collagen genes. None seem to cause hyperthyroidism, which can significantly elevate BMR. Familial neuroblastoma might increase catecholamines, potentially leading to hypermetabolism. However, Graves' disease, while not on chromosome 2, appears to increase BMR the most among all options presented.**Clarifying the prompt's requirements**\n\nThe prompt asks for a genetic disorder caused by mutations on chromosome 2 that also leads to the greatest increase in basal metabolic rate (BMR). It seems like I need to identify one disorder that meets both criteria. Familial neuroblastoma on chromosome 2 could be a candidate due to its potential to increase BMR through catecholamine secretion. However, I\u2019m still considering hyperthyroidism, especially Graves\u2019 disease, which significantly elevates BMR, but I doubt it\u2019s linked to chromosome 2. I\u2019ll need to stick with options that fit both constraints.**Evaluating familial neuroblastoma**\n\nI\u2019m checking the details around familial neuroblastoma, where ALK activation leads to catecholamine secretion. This can cause sympathetic hyperactivity and potentially moderate increases in basal metabolic rate (BMR). Harlequin ichthyosis could also cause increased energy loss, impacting BMR, but I suspect familial neuroblastoma has a larger effect due to tumor metabolic demand. The ALK gene is indeed on chromosome 2. I\u2019m leaning toward option I, as the catecholamine secretion from neuroblastoma contributes significantly to higher BMR. I'll provide a concise justification for this selection.",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "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",
                "id": "rs_0ddaaf6501ea74f601690935c059ec8195a4edeaff9469aef1",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762211263,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 1997,
        "prompt_tokens": 164,
        "total_tokens": 2161,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 1920,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.004035,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 4.1e-05,
          "upstream_inference_completions_cost": 0.003994
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "Which genetic disorder caused by mutations on chromosome 2 leads to the greatest increases to patients' basal metabolic rate? \n\nAnswer Choices:\nA. Alstr\u00f6m syndrome\nB. Menkes disease\nC. Gilbert's syndrome\nD. Ehlers\u2013Danlos syndrome\nE. Harlequin-type ichthyosis\nF. Graves' disease\nG. Sepsis\nH. Cystic fibrosis\nI. Familial neuroblastoma\n\nJ. Multiple Endocrine Neoplasia Type 2 (MEN2)"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G",
                  "H",
                  "I",
                  "J"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762211263-KkpTC86xq7xhzHIw7k5W",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"I. Familial neuroblastoma \u2014 familial cases are linked to ALK mutations on chromosome 2 (2p23); neuroblastomas often secrete catecholamines, producing a hypermetabolic state and raising basal metabolic rate.\",\"answer_letter\":\"I\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Evaluating genetic disorders and BMR**\n\nI'm thinking about Graves' disease, which is an autoimmune hyperthyroidism, and its connection to chromosome 6. I note that familial neuroblastoma is connected to the ALK gene on chromosome 2.\n\nNow, focusing on the question about which genetic disorder leads to the greatest increase in basal metabolic rate (BMR), it seems hyperthyroidism (like Graves') is the one that does this the most. But wait, it\u2019s not caused by mutations on chromosome 2. So, I'm looking for a genetic disorder associated with chromosome 2 mutations that raises BMR significantly.**Identifying chromosome 2 disorders**\n\nI\u2019m listing the genetic disorders on chromosome 2: A. Alstr\u00f6m syndrome (ALMS1 gene) is a yes. B. Menkes disease is on the X chromosome, so no. C. Gilbert's syndrome (UGT1A1) is on chromosome 2, yes. D. Ehlers\u2013Danlos syndrome has various types; the vascular type is COL3A1 on chromosome 2 but is quite diverse overall. E. Harlequin-type ichthyosis (ABCA12) is also yes. F. Graves' disease isn\u2019t a single gene and not on chromosome 2. G. Sepsis isn't genetic. H. Cystic fibrosis is out, being on chromosome 7. I. Familial neuroblastoma is on chromosome 2 (ALK). J. MEN2 is on chromosome 10. Now, among these, I'm considering which disorder leads to the greatest increase in basal metabolic rate, and familial neuroblastoma seems to increase BMR due to catecholamine production.**Assessing BMR impact of disorders**\n\nI\u2019m considering whether neuroblastoma would significantly increase basal metabolic rate (BMR). It doesn't seem like it would have a major systemic effect like hyperthyroidism does. Harlequin ichthyosis causes severe fluid loss, which might raise metabolic demands, but probably not BMR notably. Gilbert\u2019s syndrome is more mild, not affecting BMR. Alstr\u00f6m syndrome generally involves obesity and low BMR. I wonder if familial neuroblastoma could raise BMR due to catecholamine production. However, while it does increase catecholamines, it might not have a big effect on BMR compared to hyperthyroidism. But I do need to focus on the prompt here, looking for the genetic disorder on chromosome 2 that leads to the highest BMR increase!**Clarifying BMR and disorders**\n\nI\u2019m pondering whether Alstr\u00f6m syndrome, which is on chromosome 2, increases basal metabolic rate (BMR). It seems that early-onset obesity linked to Alstr\u00f6m syndrome would actually decrease BMR relative to lean mass. I think the key question is about finding which listed disorder causes the greatest increase in BMR, and that seems to be Graves' disease, or hyperthyroidism. However, I need to focus on genetic disorders specifically linked to chromosome 2 that elevate BMR. I wonder if any forms of Ehlers-Danlos could be a match, but it doesn\u2019t seem likely.**Determining BMR effects of disorders**\n\nI'm reflecting on familial neuroblastoma, which can increase catecholamines and lead to hypermetabolism. Since it's from the adrenal medulla, it secretes catecholamines, which raises the metabolic rate. That makes sense! But now I'm comparing it to Graves' disease, which significantly increases BMR due to thyroid hormones, likely more than catecholamines. However, Graves' isn't caused by mutations on chromosome 2, so I need to focus on those disorders that are. \n\nAmong options like Alstr\u00f6m syndrome, Gilbert's syndrome, and EDS, familial neuroblastoma stands out because of its catecholamine secretion effect. Therefore, I'd choose familial neuroblastoma, linked to the ALK gene, as the answer, indicating that it raises BMR significantly.",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Evaluating genetic disorders and BMR**\n\nI'm thinking about Graves' disease, which is an autoimmune hyperthyroidism, and its connection to chromosome 6. I note that familial neuroblastoma is connected to the ALK gene on chromosome 2.\n\nNow, focusing on the question about which genetic disorder leads to the greatest increase in basal metabolic rate (BMR), it seems hyperthyroidism (like Graves') is the one that does this the most. But wait, it\u2019s not caused by mutations on chromosome 2. So, I'm looking for a genetic disorder associated with chromosome 2 mutations that raises BMR significantly.**Identifying chromosome 2 disorders**\n\nI\u2019m listing the genetic disorders on chromosome 2: A. Alstr\u00f6m syndrome (ALMS1 gene) is a yes. B. Menkes disease is on the X chromosome, so no. C. Gilbert's syndrome (UGT1A1) is on chromosome 2, yes. D. Ehlers\u2013Danlos syndrome has various types; the vascular type is COL3A1 on chromosome 2 but is quite diverse overall. E. Harlequin-type ichthyosis (ABCA12) is also yes. F. Graves' disease isn\u2019t a single gene and not on chromosome 2. G. Sepsis isn't genetic. H. Cystic fibrosis is out, being on chromosome 7. I. Familial neuroblastoma is on chromosome 2 (ALK). J. MEN2 is on chromosome 10. Now, among these, I'm considering which disorder leads to the greatest increase in basal metabolic rate, and familial neuroblastoma seems to increase BMR due to catecholamine production.**Assessing BMR impact of disorders**\n\nI\u2019m considering whether neuroblastoma would significantly increase basal metabolic rate (BMR). It doesn't seem like it would have a major systemic effect like hyperthyroidism does. Harlequin ichthyosis causes severe fluid loss, which might raise metabolic demands, but probably not BMR notably. Gilbert\u2019s syndrome is more mild, not affecting BMR. Alstr\u00f6m syndrome generally involves obesity and low BMR. I wonder if familial neuroblastoma could raise BMR due to catecholamine production. However, while it does increase catecholamines, it might not have a big effect on BMR compared to hyperthyroidism. But I do need to focus on the prompt here, looking for the genetic disorder on chromosome 2 that leads to the highest BMR increase!**Clarifying BMR and disorders**\n\nI\u2019m pondering whether Alstr\u00f6m syndrome, which is on chromosome 2, increases basal metabolic rate (BMR). It seems that early-onset obesity linked to Alstr\u00f6m syndrome would actually decrease BMR relative to lean mass. I think the key question is about finding which listed disorder causes the greatest increase in BMR, and that seems to be Graves' disease, or hyperthyroidism. However, I need to focus on genetic disorders specifically linked to chromosome 2 that elevate BMR. I wonder if any forms of Ehlers-Danlos could be a match, but it doesn\u2019t seem likely.**Determining BMR effects of disorders**\n\nI'm reflecting on familial neuroblastoma, which can increase catecholamines and lead to hypermetabolism. Since it's from the adrenal medulla, it secretes catecholamines, which raises the metabolic rate. That makes sense! But now I'm comparing it to Graves' disease, which significantly increases BMR due to thyroid hormones, likely more than catecholamines. However, Graves' isn't caused by mutations on chromosome 2, so I need to focus on those disorders that are. \n\nAmong options like Alstr\u00f6m syndrome, Gilbert's syndrome, and EDS, familial neuroblastoma stands out because of its catecholamine secretion effect. Therefore, I'd choose familial neuroblastoma, linked to the ALK gene, as the answer, indicating that it raises BMR significantly.",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCTXiF8B0cpwTA_m6zCPajEXK3fpsK9Nf2-z8EJaAgZtx-aI1YsMpU9cN_UwKW3s-wGIzpRsMvpCvQIsiSDyrzyf1RpdsHmQA6EJCi_iPc0MWXdJ9_lav7MSBbNPlhvVuIB30Jhw5YVJ_F2TwOJAwjFIRIsgx1Ju-yGU3h9s4jiG3jXOo_Rwe8xZJoM8wj38YLy1i4akn1ctbZnE_yovzqwqoUCyM2JUNQnc6j3v0wH0p40OrupKFssZzn5Di2O76mLEK0DunSllX8KSegCD_u6iuCu59s_eH1QYav1RTlcFt1CV0Hy-fm1D_hm4nMH-h2lXO3ESzsReDYMkBibL4jiIFHiaGqH7EDgi-YuuUCmbjXF8Kqz107nlQMxZMrqNRlcqB6OhzWDJSOeZXWti4BfxMuxHgIR1CFoQ1jL3mjlfmDMbEqJoZtoknRTf9GfBjvvUS3kPXmYDjBhG8KTMqAmIxT0yYtNzOpLqmHnTWIgI5NHz0t6L5PO8gSMY-DbhEhaeLqfyH800bhIJKzKSACCHlKPYDaNmEEBAMFEGLU5jNEUWhD_JBwpFA8hnUf1ip0o8seozD7OvoadmyQzFhQXKfacKDFGvHXcm5Qkg6cke5tseRi7mjqB2pNXO_r0ftNrIHZXVV6bEculco6Q5oYD5FUpF-zxyylJlCOOaex6ynigGpqF93EB4se7gLWfjoz1pi8ofRwH77vjojVK1gpDOxXZ6pR8mC8jGxsP-9CujMWQJ1YZA72Z5kncA2uAKnVUMto4B0Nr4FdgGrgcLa8cLymPr2ZyEiPtu1UW7Vg_KiJIhlFSIrVzPziyUko3wLomg9ZUFdkvi_kh_HAzFJRTO9Gp5JmmhSkG7lV_RTnRVSpFVTe2MqikttGIzJ0Yfu-QVpJeyULzaWeyw64mjlHqg0qm2gvly3MJs3FTej1jT_Or1DUJQfD4_UyuScof81wCb9ngBfGjU78D80xaackoqyA0-CxTR88awb4A1TaE56wo5mhbMY5OzGHV1Zgq31bB2sS0tzZLxsWb1vxCnx9KBd-aP-X7Yai20NEEAU4qqByGVtgSCXXZccb_BdMURuKmcdEvlTQLhrw1uDZJ4Zjn7hlRpe70aO4UgM5vxrzCGtZ4x2ZShaDwd2oPo6Xkd1ZdRvbMkg6U-nKZMAbjhpxRgGtjTvesvu6WVDKIeminMAybPLwIIHUgAYgNRke6ngpwtHK1oSxS-agW3TW2Da7MTM8xhPx6f6uc-IAgz8rfPK21P-3xaJIU_TP4_ctn6QJawL6fQ_kUWZ6Y8jiQMlgc2DsNg9YyheSjOi7sJBrH5r84RGg9rjuUbKi-TelSXrzE1TNU6_GS6TE4-V8-WRq3ypk_8GF3czUF2agJ_qF9MQFNITXYA6zPcDDB7_ak7T_cW8e4bM8NwDVIdc7qKyu3pt4VXsarZAAH54BARDvpW56TE9Z0UXqA4FJHNYaIdWGSTAp73VJ6rZBaL0aZJiBG88Ma41ctmpnEHsIVdP3rBJCfxG-ADlLGPiZZ04v4KcWVPDyz5Qbd0p5BODwxByHhUS5WrSWnLJOwEmkyhEBzQYS1Onucd0LMTPW6yuwZWIoqcHlLI_T7NOSZYSbOpzqOFBCXU2bN_QJ-qOozmSYlOdXAOgcTiTPO3Ti_LY8y-hMmBpxEi1YeR1MFrwIeR5j075KtMyBkKNCjHDVMGhBzkewhkSzxkbUyqBmxqIwWiS8sWCxNoOgBQb1Z2k7fB31nQjWzZ1Pm5uUzfnxnyAAkXS0LAzo8jvCAenGc3ZdhqxgkkKHMjFH-Rd8tvxoZemFtCDKy2_QTyGT-uHQ90oE99VWetxG_IOB_QYXaZsR_fC6b5Dc4UyU4Z8eC91xvOEOeldcemePTDKgEnG2FRTHoNJr5GW2VQKZzOq-gF8MPbeS5zoOqcR4SioyDEhcmm5085vLXWJSLL8FDaQL3Y2AM4PYj0E_nioZgI3k3EmUnNsbhYd_WFAqW2NvV3sdFMfHYBRVcPhgFfH2Is3YmDzg1bQkWKPJzXw5LRNIL55PUYMiM2id6m-VZXUdtL9T2pq34EdSjfUJcGTPQVUAGRzTyixUnKciIMyYsRIT3z6mwHqudO3xI76C7eBLZwzy9IBxm8NBuBEJcLYQf3XKvi78tihfqVSsRN-SP3x57XpD1DcdFpNU4af84A5wdNYjjyTYP2xMTQuIA2sybcZu9JW_ZdyonlfWplqYNE2KLuJZMIrcOShibeUB1ZyW_PRjo4ekZrMokjLMyB6uhpCplYkTODLjac0Pg9I1y_UEyDxPlRpp8171Uzn2yqTmxX3D9pJ9EZFA2UPm_NwpQCZBUefP-vbYe8Qm8PS_o6pwgxycMq9__wNKd2ges4tXOwkuz_8up9KyYvFVyYjFkXtkd1aNNgSzy2ECK1JLicJbDYURzD90awUElyuZIwfJ3ZsQxEl6oQCbYpwg4xu0jUYqm6kkyYJTGfxrdbqSyDaIfA336JWIw9mfNC9uReGA9AZrg4U0Ywmt320kfJu9crIjFmfc7zRp9QzLrckCECSM539YlzEjXVZurIxTPhICfeGJ1QMIoNwLzOh0WuShlD_W7PqY4q_UH_6ocvvYMQgeAXcO8VT-Ye6qYK1vVsT_H48WEyXHuPHGHSlNDfxqLPsDNPXYz_V8XFLBgRZl0oCQIa0otSB-RPb27s_0dQc_UvrpO1Yh7tT6gjCe5yd6onklyRp2-RNTPbtK82j1SJvV1wAteSUOgzYrddBI2Inc3J0An-A_uPyjIt12YPGuB5MmkRjSMaOtZEB1kou9_sZ4LaZ_07P6Fxtn_FxziJtQ3ksbFWsby10vmrsJLF38uwm6CHM3CH27R_iMB4GE59H8nP32p7WI_aVnpDBP3UMp74AVHNp7wsMqtXSU4voyNkZpFDj64Mu_u-DhQktm42IVf6aQlbjG9AEpnRL99ZexfGEOfgf-mh67y1ZKSmGU10b5J4WPm_kJHS10naromztZWtyrUMho5CEiVK02A1KC2J0USqlwb5MZsFzCQWj0aqmgoey9hfngV9MeqsPrHQs4Xq1uPuD7ZgFzm4BzG65M0rlcB9FItmw0y50UqGoIalL_WF-VEOcdPycFsy9lf9PAjpprUkpLnUwjzAzH-g7k_gH4IQwkW_ObmMC0ONqASJBGvf7atCA-G-6jbM3IGm22on6P0ZflDF0nKoKeaOgwJwyjEFmXLvH0YrjFziA_4-PrkgtVHMNPv6ilJe1aj50a1DkOre71Wzs-pcazWvpaZhNXbxL0NbWaoEhJruoRVgabXn81yGJiDQRRVe_nsSl3bAzGbHzD9pKqKRnGLmfGdOU6Xqm1po3p3gED-he0D8cTjwe4EIDb4YSjdaCffu_RRI9MIEQlyQalH9KDILupGPxB75Ho3UfNsT-bjIxS-Ef_O1WktqKYv9vPs88gNBFtc-MextorkmMYs5N1tMVtqfRnj9X-Q6QtTCwhOunIsGikQA7eUdHfmeqBlDO7FaSFe2JPz2SxhNJIdOfeczd4Vmy3HcCzqZkcsXlVOVL1T3wfqbyXtPchcLjBC3b45SFPW7cVyilIJusoJKU12Z8A21u9oml_V-JUdgStnrZUdiwwxuGRb8uyYfcrusIOgU-05WYjcu44hk1zwaHm70_5DFZyJLRhkrDfEcJPNaeGOUyEQDadKqUtOl2skVU1wNCizvaxHfMYNW4Jm8m6GJuQBIfyTJCUWn1Tr3BePNNaMILucRSg4urIy7ZsWzVNwBWrNNYma-UcYew-cyqhHuRv17hwMZiyEU5ATPHJZinpn3OFO18DoSxakhzWC_dOBYxpvPYZ6CTQm2VN560y2_TQM6pCKbE6ZcvM4cEAgVhx0Sz3mbFAYF7sWqgGkFmOzK1CHU0W3t8RlyJ97tbJTVtR6bMmVIo1JXoGJ4ODkAgsTBLSQ0F7KaNzdtQPNumzPjH9SaZ7xKSD9HxxNCo1FDkltrvQHsAhkW4QMy190wEOXFBvwdo0JnNXhV6qg6G-h29NPKeNA5KoGJ7_PYEG645yznQxvv1yJjTeC5qxH22yYoGWx3swmnFXoA9BDviNVlJa_Rqi7syQrtFSnDvrzLkQSnqITpeD-Mu47NEPMwW1xVa4I5QIqTW05mis2uZ7xBV4a7NY8ZfRZOQerUy_V_c6QlSdZ2axbEmIFA0tvnk0SC7VFSGhtnWfxTK_Ed_tECB_BIkvqKoVGs-DbsP3FHwjrfPo3Sq-RYBQLi5pJHJvSrpZKlG2qhsxNTpPBU-ZCbHNRmDpZjkKDtFrsrXEUF5L2FP1kkWPibG6oQQlTG5_EnDOa6ifzlASNHt-OEMOix1WnuA0e4bA0t46Jq0gC7qnWYAFbxNwVZT9QZ92JoaYKTtrExEF3qjORLOpCY-YXJmVQDMhIJxp0ueFiRaAS8iK5hPAZa8-bmqaMlnun907cP339Tr1PeRfWFoPH-22IsKsOg31yawoGkCrjC9qqEc6HDr1vBdehBEjiQSZtkqOCpe_DmbtvdWXr1tHTt-k_DDll6Ttq5uIg5PsQgKlA1wvDOOQ44-qpwxDQOGLyVPt5vZBAVGoMRJJR8TmVXC-GwknFToAodxYfWUE1cjmULXfaocBTvC1z28lp1MtI1dayjRoVr1EpSxP1Td9YXMaev5hRJ7xB0-m56Tye1gQ9MiLoCOl2IFysuz4jjqg__cDFGy_xuhHWRo9sBKBrjcAFmEr1WzFdnUHCrFEM4hqRahYfBn91zA3XkGsNFZsYp4ms7jYJ1eyjxwjYpnFuSEosFKoaoqlSjceSxmXHkHQhaL18Goqc-Jo0WGIl_8oLtdBr-QPbjOxJI3JspHRhfIgVFt4PBoi9k-PgQgvTTcA3l7bslHZhj5uJZDETlh7x9S9nKKNe8zMgSsitfp7OvQvDQ2DwXW1ppWnTcUFrXSg1lVY-ghVpSyW_b4qVBUAbQrXEQ3e8ahK4vb4NvE88xsAkL8yEcyJNFIRgZfdYSHth7DLUu2R2nHJ3fLsHqqTT_F54htAPS9utHUnnC_xe6KWkqoWAeYZpQBLVVHKGiiXzH_gV86QYuUypvRP48K0K7CKCjTpzq718_l1dq7TylrFRQoEegSU4eLFof3d_qssoTDmKdTk1UTuUxBLKRUXL9zS32hNmjnzSClXWpbU8tpAsDyedw7gDehuFWQ1VDPIgWZQNFZ4ogs5_HAtX1pYBF4c6Xgu0ULqMvhNpmgshIKvCkGnMN2NfBX1tuyiuh5OCgZcSACjg-YJR33W5gg41QyWfobBj3nhqPOQuxBsTrk_jTyYvWp1jGUqQfuPHv631b9qmncPpIiC00iuHv8abq5N0syPXVG2_HVjO1dFg8UZnqmo1zBPWsW343bmqrhG-vBH3raspcmy8NvZs8Hfv_EEC8Fu6i2OS-YeydVuNxj9yD578Q-mD5qJNhuBIwi7PBLWLj4zFndARhADS0j9Ez0O99ppx96BDf4F4UnHmoHlAj5B_JBXnW2Hp47Ivh_25oyAODPTMLkKV_ZhYSJaaS1JhKKnyImWhjzZOIXuQLIkPxFCWF0l4Dhcv9rTlHspXhZm7ozE9DbXAg4zKiGXKPgTVCkMEYCHbZVXnCHAvcwSHxl-4gUwXf4Lz05uA5Abb8SUXueeHde9_5DWdDrol5PDP3OKIePn-8eZW_yOqzVod0kVuS1n-fwIqlqZerkKvhcpGWbpKB4lci8990KJ9VmWDzObu5vH-VCyDH-a30NDDe8H39NuYXlEyLO3pe20lL2Vus5-vhoNVTcQKd0tpWCQX3Qiphg5Wv8r3fGXjkRj4yIZquJ0hDHtlfzN-e7KL-9dVujTgnd4uu6bR1QHtanPII3L9FiPsRfJhgctVyOmNo6kqiLEYZuTYRXx95JXkbViB8clVs8yPtG2cPdzN_sXUpJQhq1NMPMKaV6v-XDtekxBQ8QZ56GsDaeLUcqECQOSH9fytDWfFYXJTM9qoFRmkmKbXACTGkEGs6QTzgpFHcRE7LgL4zkvY4StQIL_aJjbq9QsYTv9YlBJFGT5WcUsTrRaHOFIGs67mRrPoRtchGmYwR5jxtU5zCO4-xzcw-ZAgAdeli8mzwKe0dayiOoXDb06xyQLTirsw_-YYopV8Ubh9uyPlHinuzg_pyqqso2_1LKuO-DVPNEpLTdAWCE8ipWpHKsji6Fgzs5rg1OxbRBfNuPiqr03LZeeSwjGodNCSUoj1gRZMupMyW64XIS1QKbjrrYUd4gjNRsKHBq1J0PzPuRUlnSRsmZmshhCedsHqnYBhjUzh68wGBzWtqExbwLOdzURsGZVEMrlsyd7fgM9R1T-vgZADerWEIf4pYF0vQOl7UsmiNx6i8X7_ya7tozU7DOR4eq6wjkPRtJ0ermqma3pR9OPKPJ2BLPPVJIqGj9wMEAcMQcTIbscTuyr8u-PRqjTKMPTwq1_DgMQMzWu3SQ0X-vEk1X5kQd_rmUJWzlzgy0rxQ3S54CGP_HZycl9-k3zB7U1Jcq4QeUENxy2ijvvAuVMDrZeOYg7klN4wyPJuXELnT-OiedX331UxP7m17lJ6BsyqZyN8-MlABhDCXi7pFCmjnLRf7JKhghK8H8HNDa_53NLs4nXYERnV5VrPz62q65M8GHjDJBqgbUVyvqI7wFcAaQKaEo5C4L14v7CPk8OEJb11aHhfxdwpEgnLmbPb-8asD0YWNE9Zhw8sbjQk9Kf5RaXrZgSVFQ0G2ttMF_Nbl6QUyXAISmMoDvk7gqjgd3zl8Gq6Qu78CoQD-rLMSkDaR2JZsq9kHcQHuOvoyvTsxmrJUYQXfzq6pZFY5rO7_uHcq3dSNMtR1nb_GVvRknctfli3b0WXHpF6-IurlzgKAEOhCajdBcZrxmqNdyYgjgoP--5VGJt3G-dQXMPq-2M4hW1-kvaYiIsJmllOvX-UFzedvXn4VId3Vkehiw159jzVYr6FAloeASceR7nRJO4b-lEp-8Tkmoe_yx3uSL-g7BQEWCaIGd00UFCmWsot0vACU6EU6g3q1AOb5hXpYxUrVTE78rgXIktGDzdABwDKsYq-YWQNvWDhvusu83EpOKgzAWeGgLndJAJvuAk4GnCBF7Kexem7SSxrwIHLJT45hUOg6nNWz6GBDdz6TJqJbOF-RlP_5jAJHnHIy_XFwvU_W0xA6jWv3vmexlPqwCA_usNBsdcJWcohCUBok3VJHluDuEIBDbHyIC2VzLcxwz5yq1lQYpefev0ISZuNEqorFxTG4bGkdHHugVjwXP3VYkiMDIhyGM1V4ctZ9FQEiPVvrMxeWMqkKgOf6qo3Gax6nED4jydf0LJVMgI7yPzD2KPnp75w9b6K25bHaKXlD9fvW3Sp8wbXJhHAn-C26Ph9IEvoOGo0gr-V6hcTwVb-8gZku5RZGvKpCjdcasyKoRIrsClvCNF2BtkF13X5OZSg2QwOcWJhodlbmHBza9HBzZLgwD93TLU0kf2BnsS3sObvnrqhThwtqqb6OY19RtycXkstorzAyCDadvJCkBDndwSL7e6ZkhuuDVJTYaXwUgWiUWUL_zwFeFkL7okFuoTLXbv02UQ4lkS6MnTwQKMA1vpLOKdlBP_XOTDMA6x-WnPqvNe5d0NDn_WM7duFrNNEePJaIPQHVXrAH74BZcoe6dgm3FedeO0m3OZx6sKuhMA6t37uUG-T8OA0FwkWyVyxoiAX__kjv6v1t5uXO60uNTXYOYYavHBrlXElU5wzQg-_6aXqX3CW-xb_B_bT_-5bfXge0OKsJOn8rH3BtN4RFwKsx0h87NZ6p60H_x-nLXqTidFgQoU24SfEDgAvLnB372WxZS8csLWcnXJnCxvQ25GMQek6cZaDBSD4vd3lGX0AplvLNVh3G0aFjJlyCykaJphbxuJAPFcbhLelOobckRTMmFko6crxsda1KZkwWuIX92mXsAuTTNE9doqIV5RQlCftQLEBsk4GREHAzYc9EcpmBY45RFvWnqCWeuEofIWfKihS1JUbzhlmkNSktWJhAOYX2XWRufX6kC1EkXzTQYoVau9yL0TK5alh8q7K1JaHKMEoGXLLoET-ThkToQf7gMdn30lxmNnkKHkQmzawCwbZBbhEi0HscAoPIjpoQItRKKdivoNl4Ir4wui0lvBmIB_qyi7UBZvsBmtU9PZd0cZP6TJDgo9B18TGMVSTL9TnR2fUKCDRUqCEzC4iniSLjxJTIoUR5eUXLpufa9GUQbODJi8K9FVqaxfwLlREhIeZst50FDRt-zctmLWVXDWGOWCKcz_KM3c0OhnFjEri2HC8glbHN7tNzEyEa8Urg7m7tEAn91W-dXUavz5v514kdr0Kp9o7IrO-Aun6VnUXPumBEmx8ORRHLRzVrO5JjG-uDKKyRFnFkbCXsuB0AE4Gi9dRe-IKVVjIx6MToEPS1c3f4Iv710kjcdVgkOdFQCCz4UCN43vASvj8YcISAYNeJnx6ZJYUf_N4dKNvIH2kmmGeLsmI0tg7R3trqOGGS8KNIiPhj7uDo539a1463m9wECWFmVJR_H4e0sImx96-i41vS-hFOgqdBV2YFA9A1LW1EAg7GkETsdL58c1KIK8qimp69IWs2xotsukW9LnwRedOpAVVqoGjXIoAMPL3or2GMpratb9xWFJi0Kc9eCXSNxGzNAs9vc1t3WlFoMd6J0scBK-0B4Yx1STD6JMphKl5GaLc7Gb5GHViZIKrUjclauopAvqlV29axk5zR-xrVRUatEnhQ93TKWvS6oerdO6Kh7F9hEGA-WgUKncvCWggENmIb0OkM2kJOa0qFA-E6ajIy5xdTgJi5-ZSb5vRI_J9XsfqiKjNcFMo8FlknkhhLqt8KAQiQqIR9XtjB39bx1jkJjoP_NJAYTwUGvR4yazDqhZDuY6fD_GbwLQaJI3wRrnnt4LANYnheLEyLtA2t0YivrHvemKZ4NI38ntZYzqsz7saGrSp6absd4lrJ1jiOaUgt0Zkw8UTcncZCC_LKlWfpsBHUk_zMu38NtE8Fb_xo_DIg3lChYREXxxA2b4VV34WVovIQ7FSnccWWndvPWMPhSAi5J-QYG4l8qd2g8SiNGfINQEYFT-jFpNAX6EGiVX1JB4_YmqW1o-kDhm5MIuqq5toMMfH-fNAVJhWTAjEZtQ0LnPyfARGa0TsmhXN5C4Sdri1bJQaW4se4UqKXjZADZsjbhJEE_vx2J8IqXqFrr1gRd0MQZtVYzl-yUsMKBsCxDEOjispgzbc8n5_j-dVrwJsGSK5XorZfKYLXc3z3TngeC0rh9uMILyk9x4lndAd6coCsjP01cAfdn2thZgx2N5rmWPDENrXjOLHaCg8MJ0JzYFclZixJLqTwr1vOebqtt9wm-7IExrosjAx4VrC9YPPtHLHrglFHHZ56u0ksnr3Ue5rKB_O9iSMcIygBX63tKFGgVY13wSZgMFseAkNQB1n4KcoKyh6gts_q8_BGGvKZtvZ1hP3tKKpvOo7SMC2SXN350QRXAWNpVgwLJdaceLp81DPY8TafS54xa4V1i-2SH2hwazSO6--IZgjqrCpB0Q5ohvxEbFW64iVDNaVgpzu4ITBqxrTmiIdrkvzL8ZXFjzHWrkA6l_3RwijbK62LakbaWWfK4FNMCWRZJXbfsldAIaGv9j5xddSg-NgOcrXqxMzQ0TAJl8AI5ROP-2X7gMfRyQHEeQfRUrViln0lJNEtRQJhemsdRd7kidA0hoP9CyGkWw-fFQyw0CzdM6g85J6wr-CQMwSYIS3y4b-ey-NYCXUFzisSocknI1AP7GxiAAYUSIAh1iebvZQnS8YHKMudWpRV76Jveirco_w6ZN-Mtu7VlddXVRDKGJE-m1xkpYpF4-GpI2PtaNeQnoRHqCUhoDSSsLo-huyANP8EO7A8iJDKX5xQA7fmkkV17yGWEhEmuf_WAKwOI29_G_u8qQZ0mWbtoPxYRcMrhvSmTRbB23rw6Ig5oat7zmq1fk26L2Axb_k74nQPLAnq9SAxEhYewkjU0wkBHqPUhorfHCpE5ZBXkKWkCCY_gi-t_vcxDzd8_tysAgZpsDdt0QvF3PUg5x8wDbu34g0i5ZraFYlFakAxCrBR6ibbV6sgT7u_lOAe-5o5tVHRuYTuVhKMfq3LamN5IPdaoO06nHuwQ_PvNxpWEgfXvyt7THV2W03dd59oESs54QH8I-Ec5ps6K6aJk8tkecn7f9yUYBcjmVVCVt-yt9yoYzinRAzOWX2KhmvQiNNbGybCz37AJNyWF1SQVA5KDSa1Z3RXMphZ3NOcAXkPoG_R7j30G2qzD7eLR1KRbZrvh7hnyemgzomLp3MWbi3bnoL9IcUHZ3Y2Pvfso0oRh08pl9Ok45R_yFyjf8mwKTzWtlAPB2-ncZA0a5nDDsoXC-oAYacXY7BaCVlur8A4CfRwlGBm4-1BbQFk1eqOJcLPRLxXSYHDKmYnx6OSb59bRKV1Rlzw2JCbf0BQbn5gvJNVtdHZpk6E0",
                "id": "rs_05f89bfb9f15447301690935c0b8b8819689d642dc96908659",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762211263,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 1664,
        "prompt_tokens": 164,
        "total_tokens": 1828,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 1600,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.003369,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 4.1e-05,
          "upstream_inference_completions_cost": 0.003328
        }
      },
      "provider": "OpenAI"
    }
  }
]